NCT00767728View on ClinicalTrials.gov

Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis

PHASE3CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

August 31, 2007

Study Completion Date

October 31, 2007

Conditions
Ulcerative Colitis
Interventions
DRUG

Granulated mesalamine

0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.

DRUG

Placebo

Matching placebo capsules (4 capsules) were administered orally QD, in the morning.

Trial Locations (1)

65265

Mexico

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00767728 - Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis | Biotech Hunter | Biotech Hunter